|
Clinical diagnosis and Safety of Vildagliptin versus Sitagliptin with Metformin over Patients of Type-2 Diabetes Mellitus
|
|
| Author:
|
PRAVEEN YADAV, BHASKAR JOSHI, A.GEETHA BHAVANI
|
| Abstract:
|
Objective: The aim of the study to compare the efficacy of vildagliptin (50mg) and sitagliptin (50mg)
metformin (500mg) for type-2 diabetes mellitus. Methods: The treatment course duration of 28 weeks
observational comparative study was conducted over 150 patients with type-2 diabetes mellitus was diagnosed.
The group A (n=75) was treated with vildagliptin (50mg) with combination of metformin (500mg). The group B
(n=75) was treated with sitagliptin (50mg) with combination of metformin (500mg) with fixed dosage was given
daily twice. For this study T2DM patients enrolled age group of 30-70 years. Fasting plasma glucose, post
prandial glucose, glycated hemoglobin, body weight, creatinine, potassium, lipid profile test was performed. The
base line of HbA1c from >7.0% to <10.5%. Thus, performance of t-test was found to be significant role.
Results: The group A and group B have shown a greater reduction in plasma glucose fasting plasma glucose
reduced up to 48.08mg/dl (p<0.000) in vildagliptin group versus sitagliptin group 48.11 mg/dl (p<0.000),
postprandial glucose reduced up to 49.16mg/dl (p<0.000) in vildagliptin group and sitagliptin group reduced up
to 47.2mg/dl (p<0.000) and HbA1c reduced up to 0.97% (p<1.0) in vildagliptin group versus sitagliptin group
reduced up to 0.93% (p<1.0). The body weight was increased by 0.70kg with sitagliptin (Group B) and reduced
by 0.62kg with vildagliptin (Group A). Conclusion: In this study both groups produced significant
improvement in the management of blood glucose in diabetic patients and both drugs are safe. In this
observation vildagliptin group results were found to be potential treatment with more benefits with
comparison to sitagliptin. Sitagliptin was good for pancreatic beta cell, with lower risk of hypoglycemia
comparison to vildagliptin
|
| Keyword:
|
Beta-cell, Type-2 Diabetes Mellitus, Sitagliptin, Vildagliptin, Metformin.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2021.13.02.303
|
| Download:
|
Request For Article
|
|
|